GLP-1 RAs Show Mixed Pancreatitis Risk

Overview

This study found that initiation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) did not increase the 1-year rate of acute pancreatitis compared to sulfonylureas in patients with type 2 diabetes. However, there was a noted early increase in suspected drug-induced pancreatitis cases shortly after starting GLP-1 RAs, which requires careful interpretation.

Background

Understanding the safety profile of GLP-1 receptor agonists is crucial as they are increasingly prescribed for type 2 diabetes management. Concerns regarding pancreatitis risk have been a significant aspect of their clinical evaluation. This study provides insights into the relative risks associated with GLP-1 RAs compared to sulfonylureas, contributing to informed clinical decision-making.

Data Highlights

The study analyzed 333,687 patients who newly started a GLP-1 RA or a sulfonylurea from 2017 to 2023, providing a robust dataset for comparison.

Key Findings

• GLP-1 RA initiation was not associated with a higher 1-year rate of acute pancreatitis compared to sulfonylureas.
• Approximately 4 fewer cases of acute pancreatitis per 100,000 patients were observed in the GLP-1 RA group, but this estimate was imprecise.
• There was an early increase in suspected drug-induced pancreatitis cases during the first 2 months after GLP-1 RA initiation.
• GLP-1 RAs were associated with 23 additional suspected drug-induced pancreatitis cases but 17 fewer hypertriglyceridemia-associated cases.
• Semaglutide accounted for about two-thirds of GLP-1 RA use in the study cohort.
• The study's findings may not be generalizable due to the predominantly older male veteran population.

Clinical Implications

Clinicians should be aware of the early increased risk of suspected drug-induced pancreatitis when initiating GLP-1 RAs and consider close monitoring during the initial treatment period, as well as ongoing assessment of pancreatitis risk throughout therapy.

Conclusion

The findings suggest that while GLP-1 RAs do not significantly increase overall pancreatitis risk compared to sulfonylureas, there is a need for vigilance during the early treatment phase due to a transient increase in suspected drug-induced cases. Further research is needed to confirm these findings and assess their generalizability.

References

1. Yan Xie et al., BMJ Medicine, 2023 -- GLP-1 receptor agonists and risk of all cause and cause specific acute pancreatitis: target trial emulation.
2. conexiant — GLP-1 Drugs Linked to GI Effects, Uncertain Signals
3. The New Gastroenterologist — Recent Findings Link GLP-1 Receptor Agonists to Increased Risk of GERD
4. The New Gastroenterologist — Key Gastrointestinal Adverse Effects of GLP-1 Receptor Agonists: What Prescribers Need to Consider
5. retinal physician — The Effect of GLP-1RAs in Diabetic Retinopathy
6. American Diabetes Association Releases Standards of Care in Diabetes—2025
7. GLP-1 receptor agonists and the risk of acute pancreatitis: a living systematic review and meta-analysis
8. GLP-1 Drugs Linked to GI Effects, Uncertain Signals
9. Recent Findings Link GLP-1 Receptor Agonists to Increased Risk of GERD
10. Key Gastrointestinal Adverse Effects of GLP-1 Receptor Agonists: What Prescribers Need to Consider
11. GLP-1 receptor agonists and risk of all cause and cause specific acute pancreatitis: target trial emulation.